Trial Search Results
Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases
The maximum tolerated dose of 3-session (ie, treatment) stereotactic radiosurgery to treat brain metastases greater than 4.2 cm3 in size will be determined.
This study investigates if increasing radiation dose improves outcome for patients without greater toxicity (side effects).
Stanford is currently not accepting patients for this trial.
- Radiation: Fractionated Stereotactic Radiosurgery
- Procedure: Surgical resection of the tumor
- Age 18 years and older with pathologically-proven solid tumor malignancy and 1 to 4
brain metastases, one of which is 4.2 to 33.5 cm^3.
- Systemic therapy: Prior cytoxic systemic therapy must be completed ≥ 5 days prior to
radiosurgery. No concurrent cytoxic systemic therapy along with SRS. Cytoxic systemic
therapy to start ≥ 5 days after the completion of SRS.
- Prior surgery or SRS is allowed as long as the target metastatic lesion in this study
has not previously been treated with SRS.
- Ability to understand and the willingness to sign a written informed consent.
- Life expectancy of ≥ 12 weeks.
- Previously treated with whole brain irradiation
- Metastatic lesion in question has previously been treated with SRS.
- > 4 total brain metastases at the time of initial evaluation.
- Pediatric patients (age < 18), pregnant women, and those who are unable to give
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study